Driving Clinical Trial Success in Rare Diseases A Global Phase 3 Study

VRMM Stage: Pivotal Inflection

Summary

A privately-owned biotechnology company, backed by leading life science investors and over £270M in private financing, faced significant challenges running a global Phase 3 rare disease trial with a large CRO.

With slow site activation, recruitment delays, and increasing board concerns over study feasibility, the sponsor engaged Seuss+ to restore confidence, accelerate timelines, and protect budget integrity.

anaveon image 3

increase in monthly patient recruitment within 3 months

patients recruited per month sustained for 18+ months after engagement

saved in sponsor budget through contract renegotiations

What Seuss+ Delivered

Rebuilding Recruitment, Strengthening Oversight, and Restoring Confidence

Through a combination of targeted recruitment strategy, governance structures, and contract renegotiations, Seuss+ stabilized operations, restored sponsor-board confidence, and delivered measurable cost and timeline improvements.

The Risk/Challenge

M

Patient recruitment lagging, threatening critical milestones

M

Site activation rates slower than forecasted

M

Board-level concerns over study feasibility and funding impact

M

Lack of clear governance and escalation pathways with CRO

M

Contract terms limiting CRO accountability and financial flexibility

The Results

N

10x increase in monthly patient recruitment within 3 months

N

6–11 patients recruited per month sustained for 18+ months after engagement

N

£5M saved in sponsor budget through contract renegotiations

N

Board confidence in trial feasibility restored

N

Milestone timelines safeguarded

How We Helped

Recruitment Gap Analysis: Identified root causes, developed an action plan, and implemented solutions that increased recruitment rates and restored confidence in trial feasibility.

Governance Implementation: Installed a 3-tier governance framework with KPIs, clear escalation pathways, and inspection-ready documentation.

Change Order & MSA Negotiations: Renegotiated payment schedules and amended MSA terms to improve CRO accountability and strengthen the sponsor’s position.

Risk Management Setup: Created and managed a risk framework, facilitated Risk Committee meetings, and ensured transparency on key risks to protect strategic objectives.

Vendor Management Setup: Audited study systems and vendor lists, including subcontractors, to reduce study risk and enhance transparency.

Schedule a consultation now

 

Let Us Help You Meet Your Clinical and Investor Goals